In the pharmaceutical business disappointment comes with the territory. A bump in the road might become a sink-hole – a complex, seemingly insurmountable obstacle that stands between hope and despair. After nearly thirty years in the game, I’ve learned to manage through these manic episodes, but I can’t say that it gets any easier. There’s an expression something along the likes of “what doesn’t kill you makes you stronger”. Which might be a fitting analogy for some people to describe the past few months.

Temporarily putting the brakes on such an important trial was gut wrenching for everyone involved, but it was unavoidable. At Tetra, patients and patient safety and wellness comes first. We all felt, and rightly so, enormous responsibility to patients and their families and our investors. As a company that strictly conforms to GMP grade standards we acted quickly and responsibly and set about to find solutions. And that we did!

Which is my segue into believing in a “culture of the possible”- in finding a way forward using intelligence, experience and creativity, not to mention grit and very long hours. Being nimble and resourceful tested our scientific knowledge and we prevailed, even reducing the amount of time we originally anticipated for the delay.

In the final analysis, we didn’t just get back on track, we got onto a better track with a superior, new investigational drug and a far improved delivery system. With these improvements, comes a new name as well. The commercial trademark CAUMZ™ (calms) will replace PPP001 and the Phase 3 study has been aptly named SERENITY©.

Resuming the SERENITY© Study is good news for those suffering from advanced pain and associated symptoms, for our investors and for everyone waiting for evidence-based research into cannabinoid-derived pharmaceuticals. Did we make lemonade out of lemon? Not exactly, but we did prove that believing in a “culture of the possible” pays off in the end.

https://tetrabiopharma.com/investors/press-releases/press-release-details/2019/Tetra-Bio-Pharma-Resumes-its-Phase-3-Clinical-Trial-Program/default.aspx